NCT01474135已完成2 期
A Double-masked, Randomized, Controlled Study Assessing the Safety and Ocular Hypotensive Efficacy of Two AR 12286/Travoprost Fixed-dose Combination Products Compared to Travatan® Z in Patients With Elevated Intraocular Pressure
Aerie Pharmaceuticals9 个研究点 分布在 1 个国家目标入组 93 人开始时间: 2011年12月最近更新:
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 93
- 试验地点
- 9
- 主要终点
- Mean IOP across subjects within treatment group on Days 1 and 7 at each post-treatment timepoint.
研究概览
简要总结
This is a double-masked, randomized, controlled study assessing the safety and ocular hypotensive efficacy of two AR 12286/travoprost fixed-dose combination products compared to Travatan® Z in patients with elevated intraocular pressure
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 120 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18 years of age or greater.
- •Diagnosis of open angle glaucoma (OAG) or ocular hypertension (OHT).
- •Unmedicated (post-washout) IOP ≥ 24 mm Hg at 2 eligibility visits (08:00 hr), 2-7 days apart. At second eligibility visit, IOP >22 mmHg at 10:00, 12:00 and 16:00 hrs.
- •Corrected visual acuity in each eye +1.0 logMAR or better by ETDRS in each eye (equivalent to 20/200).
- •Able and willing to give signed informed consent and follow study instructions.
排除标准
- •Ophthalmic (in either eye):
- •Glaucoma: pseudoexfoliation or pigment dispersion component, history of angle closure. Note: Previous laser peripheral iridotomy is acceptable.
- •Intraocular pressure > 36 mm Hg
- •Known hypersensitivity to travoprost, any component of the formulation (benzalkonium chloride, etc.), or to topical anesthetics.
- •Previous glaucoma intraocular surgery or glaucoma laser procedures in study eye(s).
- •Refractive surgery in study eye(s) (e.g., radial keratotomy, PRK, LASIK, etc.).
- •Ocular trauma within the past six months, or ocular surgery or laser treatment within the past three months.
- •History or evidence of ocular infection, inflammation, clinically significant blepharitis or conjunctivitis at baseline (Visit 1), or of herpes simplex keratitis
- •Contact lens wear within 30 minutes of instillation of study medication.
- •Ocular medication of any kind within 30 days of Visit 1, with the exception of a) ocular hypotensive medications (which must be washed out according to the provided schedule), b) lid scrubs (which may be used prior to, but not after Visit 1) or c) lubricating drops for dry eye (which may be used throughout the study).
- •Clinically significant ocular disease (e.g. corneal edema, uveitis, severe keratoconjunctivitis sicca) which might interfere with the study, including glaucomatous damage so severe that washout of ocular hypotensive medications for one month is not judged safe (i.e., cup-disc ratio > 0.8).
- •Central corneal thickness greater than 600 µ.
- •Any abnormality preventing reliable applanation tonometry of either eye.
- •Clinically significant abnormalities in laboratory tests at screening.
- •Clinically significant systemic disease (e.g., uncontrolled diabetes, myasthenia gravis, hepatic, renal, endocrine or cardiovascular disorders) which might interfere with the study.
- •Participation in any investigational study within the past 30 days.
- •Changes of systemic medication that could have a substantial effect on IOP within 30 days prior to screening, or anticipated during the study.
- •Due to status of nonclinical safety program, women of childbearing potential who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control. An adult woman is considered to be of childbearing potential unless she is one year post-menopausal or three months post-surgical sterilization. All females of childbearing potential must have a negative urine pregnancy test result at the screening examination and must not intend to become pregnant during the study.
研究组 & 干预措施
0.25% AR-12286/ 0.004% travoprost
Experimental
Fixed dose combination of 0.25% AR-12286 and 0.004% travoprost
干预措施: 0.25% AR-12286 / 0.004% travoprost (Drug)
0.5% AR-12286/ 0.004% travoprost
Experimental
Fixed dose combination of 0.5% AR-12286/ 0.004% travoprost
干预措施: 0.5% AR-12286, 0.004% travoprost (Drug)
0.004%Travoprost
Active Comparator
Travatan(R) Z(travoprost ophthalmic solution)
干预措施: 0.004% Travoprost (Drug)
结局指标
主要结局
Mean IOP across subjects within treatment group on Days 1 and 7 at each post-treatment timepoint.
时间窗: 7 days
Intraocular pressure
次要结局
- Ocular and systemic safety(7 days)
研究者
研究点 (9)
Loading locations...
相似试验
已完成
2 期
A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 DaysOpen Angle GlaucomaOcular HypertensionNCT01789736Aerie Pharmaceuticals234
已完成
2 期
Study of an Investigational Product, QLS-111, Provided as an Eyedrop, for Treatment of Normal Tension Glaucoma (NTG)Normal Tension Glaucoma (NTG)Low-Tension Glaucoma, BilateralLow-Tension Glaucoma, Unspecified EyeGlaucomaNCT06030193Qlaris Bio, Inc.37
已完成
2 期
SYL040012, Treatment for Open Angle GlaucomaOpen Angle GlaucomaOcular HypertensionNCT02250612Sylentis, S.A.184
进行中（未招募）
1 期
A Study to Investigate the Effect of IOP-lowering With TO-O-1001 Eye Drops in Healthy Subjects and in Patients With Open-Angle Glaucoma or Ocular HypertensionOpen Angle GlaucomaOcular HypertensionNCT05456724Theratocular Biotek Co.50
已完成
2 期
Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT PatientsOpen-angle Glaucoma (OAG)Ocular Hypertension (OHT)GlaucomaNCT06249152Qlaris Bio, Inc.36